According to Arizton’s latest research report, the global biopharmaceutical contract manufacturing market is growing at a CAGR of 16.51% during 2023-2029
Looking for More Information? Click: https://www.arizton.com/market-reports/biopharmaceutical-contract-manufacturing-market
Report Scope:
Market Size (2029): $38.07 Billion
Market Size (2023): $15.22 Billion
CAGR (2023-2029): 16.51%
Historic Year: 2020-2022
Base Year: 2023
Forecast Year: 2024-2029
Market Segmentation: Product, Biologies, Expression Systems, Scale of Operations, Company Size, and Geography
Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa
The global biopharmaceutical contract manufacturing market is highly competitive and dynamic, encompassing players at national, regional, and global levels. Recent years have seen exponential growth in this market, driven by a surge in R&D activities by biopharmaceutical companies striving to deliver targeted treatments to patients.
Market Opportunities
Rapid Developments in Biopharma Contract Production Services with AI
With the growing competition across the biopharmaceutical contract manufacturing industry, vendors have advanced them with new approaches that drive their efficiency in contract manufacturing. The partnership with the right contract manufacturer is an emerging trend that led to rising advances among the vendors to stay competitive in the market. The majority of CMOs/CDMOs have developed and expanded their services to keep pace with rapidly evolving the global market. These factors attract more and more biopharma companies toward contract manufacturing and drive market growth. CMOs have advanced their performance with artificial intelligence (AI) and electronic platforms to become more cost-effective and speed up production time. With digitalizing and automating biopharma contract manufacturing services, vendors are ultimately accounting for greater efficiency to deliver products in the market with more efficiency and quality. AI integration in CMOs is rapidly growing to facilitate better risk detection and improve the quality of pharmaceutical drugs. In addition, the US FDA published a paper on AI in pharmaceutical drug manufacturing. This paper facilitates advanced manufacturing for pharmaceutical companies and CMOs/CDMOs. This supportive approach by the US FDA can significantly drive AI in biopharma contract manufacturing operations. In addition to AI, data analytics has transformed the biopharma contract manufacturing industry by harnessing huge amounts of data generated through manufacturing operations CMOs can optimize production, ensure regulatory compliance, and predict equipment failure. Predictive analytics solutions become an integral part of biopharma contract manufacturing. These predictive analytics tools and platforms enable proactive decision-making, leading to improved productivity and cost-effectiveness.
Attention Toward Specialized Capabilities and Services
In the biopharmaceutical industry, research and development, clinical trials, product approvals, and new products in the market have become more and more complex, the biopharma companies seeking more diverse, experienced, and well-established contract manufacturers. However, in recent days, with the growing attention toward more niche and care-demanding therapeutic areas, now biopharma companies looking for more specialized services and capabilities in CMOs. As the biopharmaceutical industry experiences huge competition and challenges from regulatory bodies, biopharma companies looking for CMOs that are experts in specific or single areas. This factor creates opportunities for small and emerging specialized CMOs that can offer tailored solutions and services to meet the unique requirements of biopharma companies.
Recently, biopharma companies had for CMO partners who offer more specialized services rather than just fill internal skill gaps and enable them to focus on more core competencies. With specialized CMO, biopharma companies looking for customized solutions and efficient operations. In response, CMOs have strived to actively pursue new partnerships between manufacturers with additive skill sets or complementary specialties. According to the European Pharmaceutical Review report 2023, as the complexity increases in biopharmaceutical manufacturing the attention toward specialized CMO is growing recently. For example, Antibody Drug Conjugates (ADCs) are one of the targeted therapies, in which biopharma companies seeking for more specialized CMOs/CDMOs. More than 70% of ADC manufacturing is outsourced to CMOs/CDMOs that only specialize in this category.
Monoclonal Antibodies the Fastest Growing Segment with a CAGR of 18.05%
In 2023, the monoclonal antibodies segment dominates the global biopharmaceutical contract manufacturing market. Monoclonal antibodies (mAbs) currently represent the dominant product category within biopharmaceuticals, driven majorly by the rising prevalence of – and growingly sophisticated approaches to treating complex and severe health conditions, including cancers.
Furthermore, one of the leading CDMOs, 53 Biologics reported that the research and development activities rose rapidly after the COVID-19 pandemic specifically for monoclonal antibodies. With the growing demand for more specific and immune support biopharmaceutical products, the demand for monoclonal antibody contract manufacturing is rapidly increasing across the world.
In 2020, more than 50% of biologics products reached the clinical stage (~630) at the global level. Of these, ~430 products were related to monoclonal antibodies. Moreover, most development-stage biologics are monoclonal antibodies or related mAbs. These factors indicate that there are significant opportunities for vendors to manufacture and deliver monoclonal antibody products to biopharma companies. This indicates that the rapid development of monoclonal antibody products can deliver significant opportunities for market growth.
Recent Vendors Activities
- In 2024, Sanofi one of the leading CMO invested over $1 billion investment in biomanufacturing in France to enhance medicine production capabilities in France. In 2023, GTP Bioways opened two new biopharmaceutical production facilities in France.
- In 2024, Lonza announced an agreement to Acquired Genentech manufacturing unit in the US from Roche for $1.2 billion capital.
- In 2024, Thermo Fischer Scientific acquired Olink Holding AB. Olink –a pioneer company in next-generation proteomics solution development.
- In 2023, Wuxi Biologics one of the leading market players announced that it increasing manufacturing capacity at its facility in Germany. Since 2020, the company has invested in the construction and adaptation of two new facilities in the country.
The Biopharmaceutical Contract Manufacturing Market is Booming Across APAC & North America
North America dominates the global biopharmaceutical contract manufacturing market. The market dominance of the regions is attributed to the presence of the highest number of biopharma companies, rising outsourcing of biopharma contract manufacturing due to cost and regulatory compliance factors, and the presence of several leading market players in the region.
In North America, several biopharma companies are continuously engaged in novel biologics development. Significant investments made by these companies in R&D to strengthen their pipelines for chronic autoimmune diseases are projected to boost the launch of novel therapeutics in North America. The increasing approvals for novel therapeutics have created lucrative opportunities for market growth in the region. However, the requirement of high capital investment in R&D challenges the companies for manufacturing services, where regional CMOs offer cost-effective options for those companies.
APAC is one of the best destinations for biopharmaceutical contract manufacturing due to APAC expanding rapidly as a cost-effective destination for biopharma contract manufacturing. The region is poised to become a manufacturing hub, building on its success in clinical research and biotechnology innovations. China has established itself as a biopharma manufacturing leader in the region and other countries are following suit in the region. In APAC, India, South Korea, and Singapore recently launched supportive and ambitious policies and frameworks to boost the biopharma sector and the region is gearing up for transformation in its biopharma manufacturing capacities. Furthermore, favorable tax incentives and lower manufacturing costs are two leading factors that attract biopharma companies toward the region for contract manufacturing. Furthermore, several emerging, small, and medium-sized biotech and pharma companies have newly entered the region fueling the demand for biopharma contract manufacturing.
Competitive Overview
The global biopharmaceutical contract manufacturing market report consists of exclusive data on 45 vendors. Some emerging players compete against large and small medium-sized market players. Boehringer Ingelheim, Lonza, Samsung Biologics, AbbVie, Catalent, Emergent BioSolution, FUJIFILM, Merck KGaA, Pfizer, and Wuxi Biologics are leading companies that accounted for major market share in the global biopharmaceutical contract manufacturing market. These vendors are continuously focusing on expanding their biopharmaceutical contract manufacturing services that meet clients’ requirements, international regulations, and increase the efficiency of their product, strengthen their market position.
Looking for More Information? Click: https://www.arizton.com/market-reports/biopharmaceutical-contract-manufacturing-market
Key Vendors
- Boehringer Ingelheim
- Lonza
- Samsung Biologics
- AbbVie
- Catalent
- Emergent BioSolution
- FUJIFILM
- Merck KGaA
- Pfizer
- Wuxi Biologics
- AGC Biologics
- AJINOMOTO CO., INC.
- Asymchem
- Curia Global, Inc.
- (Albany Molecular Research Inc.)
- Biocina
- Biocon
- Rentschler Biopharma
- Ascendia Pharmaceuticals
- Charles River Laboratories
- GBI
- Argan Life Sciences
- KBI Biopharma
- Sanofi
- Bavarian Nordic
- Wacker Biotech B.V (Wacker Chemie AG)
- Jubilant HollisterStier
- National Resilience
- Thermo Fisher Scientific
- Axplora
- Binex
- Canton Biologics
- Shanghai ChemPartner
- Cytovance Biologics
- Kemwell
- Midas Pharma GmbH
- Alcami Corporation
- Cambrex Corporation
- Pharmaceutics International
- Singota Solutions
- Serum Institute of India (SII)
- Recipharm AB
- Famar Health Care Services
- Vetter Pharma
- CSL – Seqirus
Segmentation & Forecast
Product
- Finished Dosage Form (FDF)
- Active Pharmaceutical Ingredients (API)
Biologics
- Monoclonal Antibodies
- Vaccines
- Other Biologics
Expression Systems
- Mammalian
- Non-mammalian
Scale of Operation
- Commercial
- Research
Company Size
- Large Companies
- Small & Mid-sized Companies
Geography
North America
- The US
- Canada
Europe
- Germany
- France
- The UK
- Switzerland
- Italy
- Spain
APAC
- China
- Japan
- South Korea
- India
- Australia
Latin America
- Brazil
- Argentina
- Mexico
Middle East & Africa
- Turkey
- Saudi Arabia
- The UAE
- South Africa
The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the biopharmaceutical contract manufacturing market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/biopharmaceutical-contract-manufacturing-market
What Key Findings Our Research Analysis Reveals?
How big is the global biopharmaceutical contract manufacturing market?
What is the growth rate of the global biopharmaceutical contract manufacturing market?
Which region dominates the global biopharmaceutical contract manufacturing market?
What are the factors driving the global biopharmaceutical contract manufacturing market growth?
Who are the major players in the global biopharmaceutical contract manufacturing market?
Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4630
Other Related Reports that Might be of Your Business Requirement
Europe E-Pharmacy Market – Focused Insights 2024-2029
https://www.arizton.com/market-reports/europe-online-pharmacy-market
Global Online Pharmacy Market – Focused Insights 2024-2029
https://www.arizton.com/market-reports/online-pharmacy-market-size-analysis
Why Arizton?
100% Customer Satisfaction
24×7 availability – we are always there when you need us
200+ Fortune 500 Companies trust Arizton’s report
80% of our reports are exclusive and first in the industry
100% more data and analysis
1500+ reports published till date
Post-Purchase Benefit
- 1hr of free analyst discussion
- 10% off on customization
About Us:
Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/biopharmaceutical-contract-manufacturing-market